h3Senior Study Manager (Immunology) /h3 pLocation: Horgen, Switzerland / United Kingdom /p pReporting to: Head of Clinical Operations /p h3Company Context /h3 pNumab Therapeutics AG is a Swiss‑headquartered biotechnology company based in Horgen, Zurich canton, dedicated to developing multi‑specific antibody‑based immunotherapies. Using its proprietary λ‑Cap™ and MATCH™ technology platforms, Numab designs and engineers multi‑specific antibodies that combine best‑in‑class potency, stability, and pharmacokinetic properties. /p pThe company has built a broad and differentiated pipeline of in‑house programs across immunology and oncology, and has established multiple collaborations with leading global pharmaceutical partners—underlining the scalability and external validation of its platform and business model. In 2024 the company completed a major transaction with Johnson Johnson through the sale of its subsidiary (Yellow Jersey Therapeutics) which included rights to NM26‑2198 in a deal valued at approximately USD1.25billion. In early 2025, the Series C fundraising was extended to CHF180million to support several first- and best-in-class programs. /p h3Role Purpose /h3 pNumab is preparing its lead inflammatory bowel disease programme for first-in-human development. This is a hands on study leadership role at a pivotal moment and the successful candidate will create clarity, pace and control across a fast moving, outsourced development model. They will be the day-to-day operational lead on a phase 1 study, partner closely with the CRO, clinical sites, vendors and internal functions to ensure sites, systems, supplies and data are ready throughout study start up and execution. /p pThe role suits a scientifically credible early phase study manager who can identify critical path dependencies, challenge partners constructively, drive issues through to resolution and who is comfortable making sound decisions in a lean biotech setting. It offers direct ownership, meaningful vendor influence and the chance to help establish the operational foundations for future studies. /p h3Key Responsibilities /h3 h3Study delivery and CRO Leadership /h3 ul liLead operational delivery of assigned Phase I studies, from start-up through close out and reconciliation /li liAct as Numab's day-to-day operational counterpart to the CRO, setting clear expectations, tracking commitments and driving timely resolution of study issues. /li liDevelop and maintain integrated study plans, milestones, risk and issue logs and decision records to expedite material risks early with practical mitigation options. /li liReview CRO deliverables, including monitoring reports, study status updates, relevant operational plans and ensure actions are owned to completion. /li liCoordinate operational readiness for dose-escalation and safety review meetings, ensuring required safety, PK and operational data are available, actions are documented and decisions are rapidly implemented across the CRO, sites and vendors. /li liSupport study governance, including preparation of concise, decision ready updates for the Head of Clinical Operations and cross-functional stakeholders. /li liContribute to operational forecasting and management of study scope, timelines, critical path dependencies, change control, budgets and vendor performance. /li liLead operational implementation of protocol amendments and study expansions, coordinating the CRO, sites and internal functions to translate approved changes into executable study plans. /li /ul h3Sites and participant operations /h3 ul liOwn the relationship with key sites for, ensuring clear operating rhythm, site readiness and ensuring timely resolution of study issues. /li liPartner with the CRO and sites to conduct and assess feasibility, select appropriate sites and drive activation readiness. /li liEnsure practical readiness for site activation, including essential documents, staff training, system access, investigational product and sample workflows, laboratory and pharmacy arrangements and recruitment plans. /li liTrack recruitment and screening performance, including site-level recruitment assumptions, screening and screen-failure metrics, recruitment forecasts and emerging enrolment risks. Work proactively with sites and the CRO to implement mitigation plans, including for barriers arising from complex eligibility criteria. /li liTravel to investigator sites when needed to support feasibility, activation, relationship management and resolution of critical study issues. /li /ul h3Data systems, supplies and quality /h3 ul liWork with CRO and relevant internal experts to support setup, testing and fit-for-purpose use of EDC and other clinical systems (for example eTMF, IRT/RTSM and safety interfaces as applicable). /li liOversee site data entry quality and timeliness, using CRO and site reporting to drive query resolution and protect data integrity. /li liCoordinate investigational product and clinical supply readiness, including forecasting,batch release and shipment to sites, reconciliation and escalation of supply risks. /li liCoordinate operational execution of PK, ADA/immunogenicity, biomarker and other protocol-defined sample strategies, ensuring collection schedules, laboratory manuals, sample logistics, assay readiness, responsibilities and data-transfer timelines are aligned across sites and vendors /li liCoordinate operational delivery across study vendors, including the CRO, central and specialist laboratories, bioanalytical partners, IRT/RTSM and other service providers, ensuring interfaces, responsibilities, timelines and escalation pathways are clear. /li liEnsure study conduct meets ICH GCP, applicable regulations, protocol requirements, SOPs and quality expectations; support audit/inspection readiness and CAPA follow-up where required. /li liPartner with Clinical, Regulatory, CMC, Biometrics, Safety and Quality colleagues to ensure operational plans align with submission, study set-up and data review needs. /li /ul h3Key Qualifications Experience /h3 ul liSubstantial clinical operations experience, including direct ownership of early phase clinical study delivery. Experience of PhI healthy volunteer and dose-escalation studies is essential. /li liStrong practical understanding of the demands of first-in-human studies, including start-up, participant safety, complex eligibility assessment, dose-escalation decision support and intensive site/CRO coordination. /li liExperience working in biotech is highly desired /li liDemonstrable experience managing CROs and clinical sites, with the confidence to challenge constructively, influence senior stakeholders and hold partners to agreed commitments. /li liExperience in country and site feasibility, activation and participant recruitment, including specialised Phase I units and multi-site patient studies. Demonstrated ability to manage recruitment challenges and site performance is strongly preferred. /li liExperience supporting studies through significant protocol amendments, cohort expansion or transition from healthy volunteers into patient populations /li liWorking knowledge of clinical data capture and trial systems, with experience supporting EDC set-up, data entry quality and operational data review. /li liExperience in inflammatory bowel disease, immunology, gastroenterology would be highly desirable /li /ul
Senior Study Manager - IBD Arbeitgeber: Forbion European Acquisition Corp
Forbion ist nicht nur eine führende Venture-Capital-Gesellschaft, sondern auch ein Ort, an dem Ihre Expertise geschätzt wird und Ihr Wachstum gefördert wird. In einem professionellen und unterstützenden Umfeld in München haben Sie die Möglichkeit, direkt Einfluss auf den Erfolg und die Reputation des Unternehmens zu nehmen, während Sie gleichzeitig von flexiblen Arbeitsmodellen und einer Kultur profitieren, die Authentizität und Teamarbeit schätzt.
Kontaktdaten:
Forbion European Acquisition Corp Recruiting-Team